Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab – a case report

Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab – a case report

IntroductionThe anti-programmed cell death protein 1 (PD-1) antibody cemiplimab has shown promising results in the treatment of unresectable or metastatic squamous cell carcinoma, however, frequently leads to immune-related adverse events limiting therapy efficacy. Although cutaneous side effects ar...

Full description

Bibliographic Details
Main Authors: Simon Fietz, Anne Fröhlich, Cornelia Mauch, Luka de Vos-Hillebrand, Tanja Fetter, Jennifer Landsberg, Friederike Hoffmann, Judith Sirokay
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Immunology
Subjects:
case report
cutaneous squamous cell carcinoma
immunotherapy
anti-PD-1 antibody
cutaneous lupus erythematosus
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1324231/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1324231/full

Similar Items